Logo

GeneTrove, Pharmacia Ink Antisense R&D Collaboration

Mar 27, 2002

NEW YORK, March 27 - Isis Pharmaceuticals on Wednesday said that its GeneTrove division will allow Pharmacia to use its antisense inhibitors to validate targets in genes that the biotech company selects.

Pharmacia will also license undisclosed IP from Isis' functional-genomics suite.

Terms of the deal call for Isis to design and deliver antisense inhibitors to Pharmacia. While financial terms of the deal were not disclosed, Isis will maintain the rights to develop antisense drugs to those genes, the company said.

 

Isis' functional-genomics IP suite comprises approximately 50 patents and applications, a main component of which is RNase H, a naturally occurring cellular enzyme that cleaves the RNA portion of an RNA/DNA duplex.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.